Cargando…

Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era

To investigate the effect of a combined immune score including the lymphocyte-to-monocyte ratio (LMR) and uninvolved immunoglobulin (u-Ig) levels on the prognosis of newly diagnosed multiple myeloma (NDMM) patients treated with bortezomib. Clinical data of 201 NDMM patients were retrospectively anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Min, Guo, Honggang, Liu, Siwei, Xu, Fangfang, Zhang, Yin, Shi, Jie, Xu, Zhiwei, Chen, Yuqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	4800
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519192/ https://www.ncbi.nlm.nih.gov/pubmed/34731142 http://dx.doi.org/10.1097/MD.0000000000027521

Ejemplares similares

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era
por: Liu, Siwei, et al.
Publicado: (2019)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report
por: Zuo, Wenli, et al.
Publicado: (2017)

Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center
por: Liu, Zhigang, et al.
Publicado: (2021)

Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies
por: Zhu, Wanqiu, et al.
Publicado: (2016)

Analysis of early death in newly diagnosed acute promyelocytic leukemia patients
por: Xu, Fang, et al.
Publicado: (2017)

Combination of low-dose rituximab, bortezomib and dexamethasone for the treatment of autoimmune hemolytic anemia
por: Yao, Mingkang, et al.
Publicado: (2022)

MiRNAs with prognostic significance in multiple myeloma: A systemic review and meta-analysis
por: Xu, Peipei, et al.
Publicado: (2019)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review
por: Yin, Shangjin, et al.
Publicado: (2023)

Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients
por: Jian, Yuan, et al.
Publicado: (2016)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Acquired hemophagocytic lymphohistiocytosis as initial manifestation of multiple myeloma: A case report and literature review
por: Mendes, Fernanda Rodrigues, et al.
Publicado: (2020)

Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy
por: Li, Tongjuan, et al.
Publicado: (2020)

Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients
por: Qin, Ya-Zhen, et al.
Publicado: (2016)

Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report
por: Shi, Xiaofeng, et al.
Publicado: (2020)

Huanglian Jiedu Decoction for treatment of multiple myeloma: A protocol for a systematic review and meta-analysis
por: An, Na, et al.
Publicado: (2020)

Treatment-related acute granulocyte–monocytic leukemia from multiple myeloma: A case report and literature review
por: Qian, Juan, et al.
Publicado: (2017)

Coexistence of nodal marginal zone B-cell lymphoma and multiple myeloma: A case report and literature review
por: Wang, Manzhi, et al.
Publicado: (2022)

Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials
por: Huang, Zeng-Yi, et al.
Publicado: (2023)

Recombinant human thrombopoietin improves the efficacy of intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor in mobilizing peripheral blood stem cells in patients with multiple myeloma: A cohort study
por: Wang, Guorong, et al.
Publicado: (2017)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
por: Mersin, Sinan, et al.
Publicado: (2021)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
por: Ashrafi, Farzaneh, et al.
Publicado: (2020)

Interleukin-6 gene-174 G/C promoter polymorphism is not associated with multiple myeloma susceptibility: evidence from meta-analysis: A systematic review and meta-analysis
por: Dong, Xiaohui, et al.
Publicado: (2021)

Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era
por: Ho, Ching-Liang, et al.
Publicado: (2015)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
por: Yimer, Habte, et al.
Publicado: (2019)

Higher single dose of bortezomib plus thalidomide and dexamethasone is a promising therapy for newly diagnosed multiple myeloma
por: Xu, Peipei, et al.
Publicado: (2019)

Bone marrow stromal cells derived exosomal miR-10a and miR-16 may be involved in progression of patients with multiple myeloma by regulating EPHA8 or IGF1R/CCND1
por: Peng, Ye, et al.
Publicado: (2021)

The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma
por: Wang, Honggang, et al.
Publicado: (2018)

Serum D-dimer as a potential new biomarker for prognosis in patients with thrombotic thrombocytopenic purpura
por: Wang, Hai-Xu, et al.
Publicado: (2020)

Recombinant human thrombopoietin promotes platelet recovery in DCAG-treated patients with intermediate-high-risk MDS/hypoproliferative AML
por: Chen, Xiangli, et al.
Publicado: (2023)

Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis
por: Sun, Chun-yan, et al.
Publicado: (2017)

Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma
por: Narsipur, Nihal, et al.
Publicado: (2021)

Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients
por: Zhou, Qiaolin, et al.
Publicado: (2022)

Primary lymphoma of the tibia in children: Two case reports
por: Suo, Haiqiang, et al.
Publicado: (2020)

Inflammatory and Nutritional Scoring System for Predicting Prognosis in Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Limei, et al.
Publicado: (2023)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma
por: Bai, Zhimin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ed4dm38n4c4tboff6lrbn4li2